Kidney and Lung ACE2 Expression after an ACE Inhibitor or an Ang II Receptor Blocker: Implications for COVID-19

Jan Wysocki; Enrique Lores; Minghao Ye; Maria Jose Soler; Daniel Batlle

doi:10.1681/ASN.2020050667

Kidney and Lung ACE2 Expression after an ACE Inhibitor or an Ang II Receptor Blocker: Implications for COVID-19

Jan Wysocki, Enrique Lores, Minghao Ye, Maria Jose Soler, Daniel Batlle^*

^*Corresponding author for this work

Medicine, Nephrology Division

Research output: Contribution to journal › Letter › peer-review

7 Scopus citations

Original language	English (US)
Pages (from-to)	1941-1943
Number of pages	3
Journal	Journal of the American Society of Nephrology
Volume	31
Issue number	9
DOIs	https://doi.org/10.1681/ASN.2020050667
State	Published - Sep 2020

ASJC Scopus subject areas

Nephrology

Access to Document

10.1681/ASN.2020050667

Cite this

@article{81aac9c727db43ba874005691bff3589,

title = "Kidney and Lung ACE2 Expression after an ACE Inhibitor or an Ang II Receptor Blocker: Implications for COVID-19",

author = "Jan Wysocki and Enrique Lores and Minghao Ye and Soler, {Maria Jose} and Daniel Batlle",

note = "Funding Information: D. Batlle was funded by National Institute of Diabetes and Digestive Kidney Diseases grant RO1DK104785. Funding Information: This work was supported by the Joseph and Bessie Feinberg Foundation (Dr. Daniel Batlle). We thank Dr. Hong D. Xiao (Providence Portland Medical Center, Portland, OR) and Dr. Kenneth E. Bernstein (Cedars Sinai, Los Angeles, CA) for generously providing kidneys from ACE deficiency models. Dr. Daniel Batlle reports nonfinancial support from Angiotensin Therapeutics Inc., outside the submitted work. Dr. Maria Jose Soler reports personal fees from AstraZeneca, nonfinancial support from Boehringer In-gelheim, nonfinancial support from Eli Lilly, personal fees and nonfinancial support from Esteve, personal fees from FMC, personal fees from Janssen, personal fees from Mundi-pharma, and personal fees from NovoNordisk, outside the submitted work.",

year = "2020",

month = sep,

doi = "10.1681/ASN.2020050667",

language = "English (US)",

volume = "31",

pages = "1941--1943",

journal = "Journal of the American Society of Nephrology : JASN",

issn = "1046-6673",

publisher = "American Society of Nephrology",

number = "9",

}

TY - JOUR

T1 - Kidney and Lung ACE2 Expression after an ACE Inhibitor or an Ang II Receptor Blocker

T2 - Implications for COVID-19

AU - Wysocki, Jan

AU - Lores, Enrique

AU - Ye, Minghao

AU - Soler, Maria Jose

AU - Batlle, Daniel

N1 - Funding Information: D. Batlle was funded by National Institute of Diabetes and Digestive Kidney Diseases grant RO1DK104785. Funding Information: This work was supported by the Joseph and Bessie Feinberg Foundation (Dr. Daniel Batlle). We thank Dr. Hong D. Xiao (Providence Portland Medical Center, Portland, OR) and Dr. Kenneth E. Bernstein (Cedars Sinai, Los Angeles, CA) for generously providing kidneys from ACE deficiency models. Dr. Daniel Batlle reports nonfinancial support from Angiotensin Therapeutics Inc., outside the submitted work. Dr. Maria Jose Soler reports personal fees from AstraZeneca, nonfinancial support from Boehringer In-gelheim, nonfinancial support from Eli Lilly, personal fees and nonfinancial support from Esteve, personal fees from FMC, personal fees from Janssen, personal fees from Mundi-pharma, and personal fees from NovoNordisk, outside the submitted work.

PY - 2020/9

Y1 - 2020/9

UR - http://www.scopus.com/inward/record.url?scp=85090174789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85090174789&partnerID=8YFLogxK

U2 - 10.1681/ASN.2020050667

DO - 10.1681/ASN.2020050667

M3 - Letter

C2 - 32669323

AN - SCOPUS:85090174789

VL - 31

SP - 1941

EP - 1943

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 9

ER -